A person who died after getting AstraZeneca jab confirmed to have had blood clots: authorities
This file photo taken on March 11, 2021, shows vials of the AstraZeneca COVID-19 vaccine in Paris. AFP
South Korean health authorities said Wednesday that the rollout of the AstraZeneca COVID-19 vaccine will continue despite major European countries' decision to pause vaccinations to investigate reported side effects.
The Korea Disease Control and Prevention Agency (KDCA) said in a press release that there is no evidence suggesting correlation between vaccines manufactured by British-Swedish pharmaceutical giant AstraZeneca and Oxford University and reports of blood clots in some recipients.
A total of some 20 European countries, including Germany, France and Italy, have suspended use of AstraZeneca's vaccine pending the outcome of investigations into blood cots in people who had received it.
International regulators, however, have said there is no proven evidence that the shots are related to the blood clots. The World Health Organization said the risk of hospitalization and death outweigh the risks of possible side effects.
Europe's medicines watchdog, the European Medicines Agency (EMA), is also scheduled to hold a meeting Thursday (local time) to review the issue and announce the result.
Meanwhile the KDCA said that one suspected case of blood clots after receiving an AstraZeneca vaccine injection has been reported.
One person who died within days of receiving the AstraZeneca vaccine is confirmed to have had blood clots. The country has reported 16 deaths after the administration of AstraZeneca products, with the authorities tentatively concluding that there is no causal relation.
"One of the reported death cases was confirmed to have blood clots during an autopsy, and we plan to review the case," KDCA chief Jeong Eun-kyeong said during a meeting at the parliament.
The reported case involves a woman in her 60s, who had previously been admitted at a long-term care facility.
Earlier, South Korea decided to expand the use of AstraZeneca's COVID-19 vaccine to people aged 65 and older to ramp up the nationwide vaccination campaign as new overseas studies showed its effectiveness.
A total of 570,000 million people in the country have already been administered with the product.
On Wednesday, the country reported 469 more cases of the new coronavirus, bringing the total caseload to 96,849, the KDCA said. (Yonhap)